Re: more assumptions stood on their ear: pCR after neoadjuvant treatment for her2+ br
Isn't this pretty much in line with what we already knew about ER+ cancers in general? Somewhat of a paradox that they are much less likely to achieve a neoadjuvant PCR but that they are also less likely to recur. It's looking like it's the ER that makes the difference in this predictive PCR piece, with HER2 being irrelevant. For example, PCR seems important to prognosis for TNBC also. Right? Am I missing something more complex?
Debbie Laxague
|